Efficacy Evaluation of Metabolic, Anti-inflammatory, and Antioxidative Factors of Irbesartan/Atorvastatin Fixed-dose Combination in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension, With Adequately Controlled Blood Glucose Levels
Phase of Trial: Phase IV
Latest Information Update: 07 May 2017
At a glance
- Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
- Indications Hyperlipidaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 04 May 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 04 May 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.